Get started
Author

Germaine D. Agollah

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
2023 · Rohit Loomba, Arun J. Sanyal, et al. · New England Journal of Medicine · 520
PDF
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
2023 · Deepak L. Bhatt, Harold E. Bays, et al. · Nature Medicine · 120
PDF
Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells
2010 · Laura B. Carpin, Lissett R. Bickford, et al. · Breast Cancer Research and Treatment · 113
Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy
2009 · Lissett R. Bickford, Germaine Agollah, et al. · Breast Cancer Research and Treatment · 53
Two-Dimensionality of Yeast Colony Expansion Accompanied by Pattern Formation
2014 · Lin Chen, Javad Noorbakhsh, et al. · PLoS Computational Biology · 46
PDF
Spatio-Temporal Changes of Lymphatic Contractility and Drainage Patterns following Lymphadenectomy in Mice
2014 · Sunkuk Kwon, Germaine D. Agollah, et al. · PLoS ONE · 40
PDF
In Vivo Lymphatic Imaging of a Human Inflammatory Breast Cancer Model
2014 · Germaine D. Agollah, Grace Wu, et al. · Journal of Cancer · 24
PDF
Direct visualization of changes of lymphatic function and drainage pathways in lymph node metastasis of B16F10 melanoma using near-infrared fluorescence imaging
2013 · Sunkuk Kwon, Germaine D. Agollah, et al. · Biomedical Optics Express · 23
Altered lymphatic function and architecture in salt-induced hypertension assessed by near-infrared fluorescence imaging
2012 · Sunkuk Kwon, Germaine D. Agollah, et al. · Journal of Biomedical Optics · 23
PDF
Evidence for SH2 Domain-Containing 5′-Inositol Phosphatase-2 (SHIP2) Contributing to a Lymphatic Dysfunction
2014 · Germaine D. Agollah, Manuel L. Gonzalez-Garay, et al. · PLoS ONE · 19
PDF
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy‐confirmed nonalcoholic steatohepatitis
2023 · Naim Alkhouri, Donald Lazas, et al. · Alimentary Pharmacology & Therapeutics · 18
Dextran sulfate sodium-induced acute colitis impairs dermal lymphatic function in mice
2015 · Germaine D Agollah · World Journal of Gastroenterology · 14
Study Design of a Phase 3 Randomized Controlled Trial Evaluating the Efficacy and Safety of Pegozafermin in Patients with Severe Hypertriglyceridemia
2024 · Cynthia Hartsfield, Deepak Bhatt, et al. · Journal of clinical lipidology · 4
Rapid Stereomicroscopic Imaging of HER2 Overexpression inEx VivoBreast Tissue Using Topically Applied Silica-Based Gold Nanoshells
2012 · Lissett R. Bickford, Robert J. Langsner, et al. · Journal of Oncology · 4
PDF
Pegozafermin Provides Beneficial Lipid Effects in Subjects With Severe Hypertriglyceridemia Regardless of Background Lipid Modifying Therapy Status: an Analysis of the Phase 2 Entrigue Study
2023 · Deepak L. Bhatt, Harold E. Bays, et al. · Journal of the American College of Cardiology · 2
Pegozafermin improved liver histology, liver-related non-invasive tests (NITs) and metabolic profiles in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)
2022 · Rohit Loomba, Naim Alkhouri, et al. · Journal of Hepatology · 2
Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)
2022 · Naim Alkhouri, Rohit Loomba, et al. · Journal of Hepatology · 2
OS-118 Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis
2024 · Rohit Loomba, Manal F. Abdelmalek, et al. · Journal of Hepatology · 1
Pegozafermin, a FGF21 Analog, for the Treatment of Non-alcoholic Steatohepatitis (NASH) Patients with F2/F3 Fibrosis
2024 · Deepak L. Bhatt, Arun J. Sanyal, et al. · Metabolism · 1
Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)
2023 · Rohit Loomba, Arun Sanyal, et al. · Journal of Hepatology · 1
Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH)
2023 · Naim Alkhouri, Rohit Loomba, et al. · Metabolism · 1
Pegozafermin Improved Liver Histology, Liver-related Non-invasive Tests (NITs) and Metabolic Profiles in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis
2023 · Rohit Loomba, Naim Alkhouri, et al. · Metabolism · 1
Abstract P5-01-04: In vivo lymphatic imaging of a human inflammatory breast cancer model
2015 · Sunkuk Kwon, Germaine Agollah, et al. · Cancer Research · 1
Triglyceride Reduction With Pegozafermin Is Highly Correlated Across Metabolic Dysfunction-associated Steatohepatitis and Severe Hypertriglyeridemia
2025 · Kevin C. Maki, Teresa Parli, et al. · Journal of the American College of Cardiology
SAT-203 Pegozafermin added to background GLP-1 therapy in patients with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: ENLIVEN 48-week extension data
2024 · Arun J. Sanyal, Manal F. Abdelmalek, et al. · Journal of Hepatology
Works count: 35
Citation count: 1,033
H-index: 12
I10-index: 12
Year
Topic
Type